Roche Review Means Major Changes

October 2010
Pharmaceutical Representative;Oct2010, Vol. 40 Issue 10, p8
The article reports on the cost-cutting plan created of F. Hoffmann-La Roche Ltd. (Roche) which aims to reduce costs while improving effectiveness and productivity following the continuous pressure to control healthcare costs.


Related Articles

  • Roche Profit Drops on One-off Costs.  // MondayMorning;10/22/2012, Vol. 20 Issue 40, p1 

    The article offers information on the economic trend of Basel, Switzerland-based Roche Holding AG. It states that the company's profit went down by 17 percent but still it managed to maintain significant rise in core operating figures because of increased sales of cancer drugs and cost-cutting...

  • Roche Steps Back from RNA Interference, Cuts 6% of Staff. Shaffer, Catherine // BioWorld Today;11/18/2010, Vol. 21 Issue 224, p1 

    The article reports on the plan of Roche AG to discontinue its preclinical research in the area of RNA interference (RNAi) as part of a cost-cutting corporate restructuring as of November 2010. According to Roche spokesman Darien E. Wilson, the company will instead focus its resources on Phase...

  • Pharma shake ups may effect retail drug, eventually. West, Diane // Drug Store News;7/23/2001, Vol. 23 Issue 9, p18 

    Focuses on the cost-cutting measures taken by major pharmaceutical companies in the United States. Workforce reduction plans of Roche Holding AG and GlaxoSmithKline; Reason behind the cost-cutting measures trend; What prompted Glaxo to merge with SmithKlineBeecham.

  • SNDA FILED FOR XENICAL AS TYPE 2 DIABETES TREATMENT OPTION.  // Worldwide Biotech;May2001, Vol. 13 Issue 5, p3 

    Reports that Roche has announced that a supplemental New Drug Application has been submitted to the United States Food and Drug Administration for Xenical.

  • Roche moves OTC work in central Europe to Saatchi.  // Advertising Age's Euromarketing;8/6/96, Vol. 9 Issue 47, p1 

    Reports that Roche Consumer Health of eastern Europe has awarded Saatchi & Saatchi the advertising accounts for its Supradyn, Rennie, Aspro and Bepanthene brands. Value of the account.

  • Roche invests in proteomics programme.  // Life Science Today;Dec2000, Vol. 1 Issue 6, p7 

    Focuses on the total amount of money allotted by Roche to link proteomics research in the pharmaceuticals and diagnostics division of the company in Switzerland. Description of proteomics; Accounts on the gene function in the post-genomic era; Identification of the protein used as potential...

  • Roche. Valdmanis, Thor // Financial World;5/20/96, Vol. 165 Issue 8, p24 

    Features Swiss drugmaker Roche. Merger of Roche's rivals Sandoz and Ciba-Geigy; Displacement of Roche as a Switzerland's top pharmaceutical concern; Growing trend towards large pharmaceutical companies worldwide.

  • No sale.  // WWD: Women's Wear Daily;2/7/1997, Vol. 173 Issue 26, p10 

    Reports on the impact of Roche Holdings Ltd.'s announcement to acquire a United States-based flavors business on speculations about the sale of Givaudan-Roure, its fragrance flavors division.

  • Roche rush.  // njbiz;7/2/2012, Vol. 25 Issue 27, p11 

    The article contends that to say that the decision of pharmaceutical company Roche to close its Nutley, New Jersey, operation came as a shock would be an understatement.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics